bluuebunny/crossref_metadata_2025_split huggingface dataset:
Small molecule agents targeting the p53‐MDM2 pathway for cancer therapy
Authors: Wang Weisi , Hu Yongzhou 
Published: January 2011

AbstractThe powerful tumor suppressor p53 takes charge of a regulatory network to guard over the living cells from harmful effect of different forms of stress and eradicate the tumor cells for normal physiological condition maintenance. However the antitumor function of p53 is often attenuated or even omitted mainly due to two alternative mechanisms, direct gene alterations in p53 or negative controlled by MDM2 protein. In this article, overview on different therapeutic strategies that are exploited to restore the neoplasm therapeutic effect to p53 will be provided, including pharmacological rescue of mutant p53 and modulation of the p53‐MDM2 interaction. We attempt to focus on the medicinal chemistry aspects of small molecule agents targeting the p53‐MDM2 pathway and recent progress in these agents. In addition, the mechanism of action and anticancer activity of different classes of compounds targeting the p53‐MDM2 pathway, as well as structure–activity relationships, are discussed.
Immunotherapeutic strategies for cancer treatment: A novel protein transfer approach for cancer vaccine development
Authors: Shashidharamurthy Rangaiah , Bozeman Erica N. , Patel Jaina , Kaur Ramneet , Meganathan Jeyandra , Selvaraj Periasamy 
Published: January 2011

AbstractCancer cells have developed numerous ways to escape immune surveillance and gain unlimited proliferative capacity. Currently, several chemotherapeutic agents and radiotherapy, either alone or in combination, are being used to treat malignancies. However, both of these therapies are associated with several limitations and detrimental side effects. Therefore, recent scientific investigations suggest that immunotherapy is among the most promising new approaches in modern cancer therapy. The focus of cancer immunotherapy is to boost both acquired and innate immunity against malignancies by specifically targeting tumor cells, and leaving healthy cells and tissues unharmed. Cellular, cytokine, gene, and monoclonal antibody therapies have progressively become promising immunotherapeutic approaches that are being tested for several cancers in preclinical models as well as in the clinic. In this review, we discuss recent advances in these immunotherapeutic approaches, focusing on new strategies that allow the expression of specific immunostimulatory molecules on the surface of tumor cells to induce robust antitumor immunity.
Resveratrol prevents embryonic oxidative stress and apoptosis associated with diabetic embryopathy and improves glucose and lipid profile of diabetic dam
Authors: Singh Chandra K. , Kumar Ambrish , Hitchcock David B. , Fan Daping , Goodwin Richard , LaVoie Holly A. , Nagarkatti Prakash , DiPette Donald J. , Singh Ugra S. 
Published: January 2011

AbstractScope: Diabetic embryopathy, a consequence of diabetic pregnancy, is associated with increase in embryonic oxidative stress and apoptosis, which lead to severe embryonic damage at early stage of organogenesis.Methods and results: This study investigated if resveratrol, found in red grapes and blue‐berries, may prevent diabetes‐induced oxidative stress and apoptosis in embryos and have beneficial effects in diabetic dams. A rodent model of diabetic embryopathy was used. Diabetes was associated with lowered reduced glutathione levels (26.98%), increased total thiol (100.47%) and lipid peroxidation (124.73%) in embryos, and increased blood sugar (384.03%), cholesterol (98.39%) and triglyceride (1025.35%) in diabetic dams. Increased apoptosis (272.20%) was also observed in the embryos of diabetic dams. Administration of resveratrol (100 mg/kg body weight (b.w.)) during pregnancy prevented both oxidative stress and apoptosis in embryos. Resveratrol reduced embryonic maldevelopment by improving embryo weight (41.23%), crown rump length (16.50%) and somite number (11.22%). It further improved the glucose (33.32%) and lipid (cholesterol 41.74%, triglyceride 60.64%) profile of the diabetic dams, which also represents the protective role of resveratrol in diabetes.Conclusion: Resveratrol was found to prevent embryonic oxidative stress and apoptosis. It also improved glucose and lipid profile of diabetic dams, indicating the beneficial effects in diabetic pregnancy.
CMOS quadrature voltage‐controlled oscillator using the diode coupling technique
Authors: Jang Sheng‐Lyang , Chang Chia‐Wei , Yeh Hsiu‐An , Juang Miin‐Horng , Song Yi‐Jhe 
Published: January 2011

AbstractA diode‐ring coupling technique has been used to design quadrature voltage‐controlled oscillators (QVCOs), which consist of two n‐core VCOs.The proposed CMOS QVCOs have been implemented with the TSMC 0.18 μm CMOS technology. A single‐band and a dual‐band QVCOs have been implemented to support the feasibility of the coupling technique. The die area of the single‐band QVCO is 0.506 × 0.905 mm2. At the supply voltage of 0.54 V, the total power consumption is 1.78 mW. The free‐running frequency of the QVCO is tunable from 4.295 to 5.185 GHz as the tuning voltage is varied from 0.0 to 1.1 V. The measured phase noise at 1 MHz frequency offset is −114 dBc/Hz at the oscillation frequency 4.587 GHz, and the figure of merit of the proposed QVCO is −184.73 dBc/Hz. © 2011 Wiley Periodicals, Inc. Microwave Opt Technol Lett 53:551–553, 2011; View this article online at wileyonlinelibrary.com. DOI 10.1002/mop.25774
Enhanced gain dual band patch antenna based on complementary rectangular split‐ring resonators
Authors: Ortiz N. , Falcone F. , Sorolla M. 
Published: January 2011

AbstractA simple and successful dual band patch vertical polarized rectangular antenna design is presented. The dual band antenna is designed etching a complementary rectangular split ring resonator in the patch of a conventional rectangular patch antenna. Furthermore, a miniaturization of the conventional rectangular patch antenna and an enhancement of the complementary split ring resonator resonance gain are achieved. The dual band antenna design has been made feasible due to the quasi‐static resonance property of the complementary split ring resonators. The simulated results are compared with measured data and good agreement is reported. © 2011 Wiley Periodicals, Inc. Microwave Opt Technol Lett 53:590–594, 2011; View this article at wileyonlinelibrary.com. DOI 10.1002/mop.25797
24‐GHz transceiver patch array front‐end with a balanced Tx leakage canceller
Authors: Lee Han‐Lim , Son Wang‐Ik , Yu Jong‐Won 
Published: January 2011

AbstractA new 24‐GHz transceiver patch array with a balanced Tx leakage canceller insensitive to antenna impedance variation and mutual coupling among ports is proposed. Consisting of two quadrature hybrids, two ring hybrids, and 4‐port feed antenna, high transmit/receive (Tx/Rx) isolation is maintained regardless of antenna impedance variation and antenna mutual coupling. The proposed 4‐port feed antenna is configured by dual fed 2x1 patch array having 6.12 and 5.06 dBi of measured Tx and Rx peak gain, respectively. In addition, the proposed architecture undergoes no power loss because of load termination (usually 50 Ω) in both transmit and receive paths. The proposed architecture obtains the measured Tx/Rx isolation of more than −40 dB stable at 24 GHz regardless of the antenna impedance variation. © 2011 Wiley Periodicals, Inc. Microwave Opt Technol Lett 53:559–562, 2011; View this article online at wileyonlinelibrary.com. DOI 10.1002/mop.25815
A new approach to autocalibrated dynamic parallel imaging based on the Karhunen‐Loeve transform: KL‐TSENSE and KL‐TGRAPPA
Authors: Ding Yu , Chung Yiu‐Cho , Jekic Mihaela , Simonetti Orlando P. 
Published: January 2011

AbstractTSENSE and TGRAPPA are autocalibrated parallel imaging techniques that can improve the temporal resolution and/or spatial resolution in dynamic magnetic resonance imaging applications. In its original form, TSENSE uses temporal low‐pass filtering of the undersampled frames to create the sensitivity map. TGRAPPA uses a sliding‐window moving average when finding the autocalibrating signals. Both filtering methods are suboptimal in the least‐squares sense and may give rise to mismatches between the undersampled k‐space raw data and the corresponding coil sensitivities. Such mismatches may result in aliasing artifacts when imaging patients with heavy breathing, as in real‐time imaging of wall motion by MRI following a treadmill exercise stress test. In this study, we demonstrate the use of an optimal linear filter, i.e., the Karhunen‐Loeve transform filter, to estimate the channel sensitivity for TSENSE and acquire the autocalibration signals for TGRAPPA. Phantom experiments show that the new reconstruction method has comparable signal‐to‐noise ratio performance to traditional TSENSE/TGRAPPA reconstruction. In vivo real‐time cardiac cine experiments performed in five healthy volunteers post‐exercise during rapid respiration show that the new method significantly reduces the chest wall aliasing artifacts caused by respiratory motion (P < 0.001). Magn Reson Med, 2011. © 2011 Wiley‐Liss, Inc.
Human skeletal remains from a multiple burial associated with the mutiny of the VOC Retourschip Batavia, 1629
Authors: Franklin D. 
Published: January 2011

ABSTRACTOn 4 June 1629, the Verenigde Oostindische Compagnie (VOC) Retourschip Batavia wrecked on Morning Reef in the Houtman Abrolhos, approximately 65 km off the Western Australian coast. The macabre events that followed the wrecking saw more than 100 individuals murdered over a three‐month period by mutineers attempting to establish control of the surviving crew and passengers. The mutineers, however, never realised their ultimate objective of hijacking the anticipated rescue ship, and most were instead duly executed in the Abrolhos. Cultural and physical material directly associated with the Batavia mutiny has since been recovered, primarily from Beacon Island, which was the focal area of the mutinous attempts to establish control.Between 1960 and 1964, four individual burials were recovered on Beacon Island; a further six individuals were recovered from a multiple grave that was excavated in stages between 1994 and 2001. The focus of the present study, however, is to briefly describe the skeletal remains of the multiple burial individuals only, including their demographics (sex, age and stature) and descriptions of potential palaeopathology (trauma, nutritional deficiencies and disease). Osteological analyses indicated an unbalanced sex ratio in favour of males; the age at death distribution ranges from about 8 months to no older than 35–49 years. It appears that prior to their untimely demise, the multiple burial individuals were mostly healthy, with relatively little evidence of disease, illness or ante‐mortem trauma. Copyright © 2011 John Wiley & Sons, Ltd.
Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression
Authors: Bouwman Peter , Drost Rinske , Klijn Christiaan , Pieterse Mark , Gulden Hanneke van der , Song Ji‐Ying , Szuhai Karoly , Jonkers Jos 
Published: January 2011

AbstractPALB2 interacts with BRCA1 and BRCA2 in supercomplexes involved in DNA repair via homologous recombination. Heterozygous germline mutations in PALB2 confer a moderate risk of breast cancer, while biallelic PALB2 mutations are linked to a severe form of Fanconi anaemia characterized by early childhood solid tumours and severe chromosomal instability. In contrast to BRCA1‐ or BRCA2‐associated cancers, breast tumours in heterozygous PALB2 mutation carriers do not show loss of the wild‐type allele, suggesting PALB2 might be haploinsufficient for tumour suppression. To study the role of PALB2 in development and tumourigenesis, we have generated Palb2GT mouse mutants using a gene trap approach. Whereas Palb2GT/GT homozygous mutant embryos died at mid‐gestation due to massive apoptosis, Palb2GT/+ heterozygous mice were viable and did not show any obvious abnormalities. Deletion of p53 alleviated the phenotype of Palb2GT/GT embryos, but did not rescue embryonic lethality. In addition, loss of p53 did not significantly collaborate with Palb2 heterozygosity in tumourigenesis in heterozygous or homozygous p53 knockout mice. Tumours arising in Palb2GT/+;p53+/− or Palb2GT/+;p53−/− compound mutant mice retained the wild‐type Palb2 allele and did not display increased genomic instability. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
The cost of childhood cancer from the family's perspective: A critical review
Authors: Tsimicalis Argerie , Stevens Bonnie , Ungar Wendy J. , McKeever Patricia , Greenberg Mark 
Published: January 2011

AbstractThe costs incurred by the families of children with cancer remain under researched. The objectives were to systematically review the literature and identify research and clinical implications. Thirteen studies were critically appraised using the Pediatric Quality Appraisal Questionnaire (PQAQ) [Ungar and Santos. Value Health 2003; 6:584–594]. Existing research indicates that families incur significant variable costs throughout cancer treatment. However, problems with the published studies related to various PQAQ domains (e.g., time horizon, sensitivity analysis) rendered the magnitude of families' childhood cancer costs somewhat uncertain. Strategies for enhancing the quality of childhood cancer cost of illness research are presented. Implications for clinical practice are discussed. Pediatr Blood Cancer 2011;56:707–717. © 2011 Wiley‐Liss, Inc.
Feasibility and parent satisfaction of a physical therapy intervention program for children with acute lymphoblastic leukemia in the first 6 months of medical treatment
Authors: Gohar Shadi Farzin , Comito Melanie , Price Jennifer , Marchese Victoria 
Published: January 2011

AbstractBackgroundChildren with acute lymphoblastic leukemia (ALL) are at risk for developing musculoskeletal complications during and after their medical treatment. The objective of this study was to examine the feasibility of an in‐hospital physical therapy‐ and home exercise program during the first four phases of medical treatment, for children with newly diagnosed ALL.ProcedureNine patients, between the ages of 2–14 years old were enrolled within 2 weeks of diagnosis in the study. Each patient was evaluated at study entry, after each of the first four phases of therapy and each time patients were re‐admitted to the hospital. Following the initial physical therapy evaluation an individualized home exercise program was developed, consisting of stretching, strengthening, and aerobic exercises. The following end points were measured at each evaluation: gross motor assessment as measured by gross motor function measure (GMFM), health‐related quality of life as measured by the PedsQL and parent satisfaction questionnaire.ResultsThis study was feasible with 98% of the evaluation sessions completed. The GMFM and PedsQL improved steadily throughout the study; however, the PedsQL slightly decreased from interim maintenance to delayed intensification. The parents reported being satisfied with the physical therapy program.ConclusionWe demonstrated that an in‐hospital‐ and home exercise physical therapy program during the first four phases of medical treatments is feasible for children with ALL. Future randomized studies are needed to confirm whether an initial physical therapy program at diagnosis in children with ALL will limit functional impairments, improve overall fitness and increase health‐related quality of life. Pediatr Blood Cancer 2011;56:799–804. © 2011 Wiley‐Liss, Inc.
Acute promyelocytic leukemia following chemotherapy for EBV‐associated hemophagocytic lymphohistiocytosis
Authors: Sathiyamoorthy Srividya , Shad Aziza , Ozdemirli Metin 
Published: January 2011

AbstractWe report a case of chemotherapy‐related acute promyelocytic leukemia (APL) following therapy with VP‐16/etoposide for EBV‐associated hemophagocytic lymphohistiocytosis (HLH). A 17‐month‐old male presented with fever and lymphadenopathy. Bone marrow and liver biopsies showed hemophagocytosis. He responded well to chemotherapy including dexamethasone, VP‐16/etoposide, and cyclosporine. One and a half year later, he developed fever and pancytopenia. Clinical work‐up revealed APL with t(15;17)(q22;q12);PML‐RARα translocation. He underwent chemotherapy for APL and is in remission 8 years after diagnosis. Alternative non‐leukemogenic agents to effectively treat HLH would be desirable. Pediatr Blood Cancer 2011;56:850–852. © 2011 Wiley‐Liss, Inc.
Mesoblastic nephroma: A report of the United Kingdom children's cancer and leukaemia group (CCLG)
Authors: England Richard J. , Haider Nadeem , Vujanic Gordan M. , Kelsey Anna , Stiller Charles A. , Pritchard‐Jones Kathy , Powis Mark 
Published: January 2011

AbstractBackgroundMesoblastic nephroma (MN) is a rare tumour which occurs mainly in early infancy and for which primary nephrectomy is the treatment of choice. This study aimed to assess surgical complications and outcomes in this patient group and to re‐evaluate the age threshold of 6 months for recommending primary nephrectomy.ProcedureA retrospective file review of all cases of MN registered in UK Children's Cancer and Leukaemia Group renal tumour trials between October 1991 and March 2008. Data from the trials were compared with data held by the National Registry of Childhood Tumours, Oxford.ResultsForty‐seven (3.5%) confirmed cases of MN were found among 1346 registered renal tumours. Median age at diagnosis was 30 days (range birth‐3.8 years). MN was significantly more common in the first 3 months of life compared to between 3 and 6 months (33 vs. 2 cases). Seven cases occurred between 6 months and 1 year and only five cases occurred beyond 1 year of age. There was a significant difference in the age of diagnosis by histological subtype. There were 11 complications in the series; no registered patient developed a recurrent tumour; and all were alive at last follow‐up.ConclusionsOutcome for children with MN is excellent at all ages, with little indication for adjuvant chemotherapy. Children presenting at <3 months of age, should be treated by primary nephrectomy. In those presenting aged >3 months, alternative diagnoses should be considered, especially in the presence of surgical risk factors. Pediatr Blood Cancer 2011;56:744–748. © 2011 Wiley‐Liss, Inc.
The current status of follow‐up services for childhood cancer survivors, are we meeting goals and expectations: A report from the consortium for New England childhood cancer survivors
Authors: Kenney Lisa B. , Bradeen Heather , Kadan‐Lottick Nina S. , Diller Lisa , Homans Alan , Schwartz Cindy L. 
Published: January 2011

AbstractBackgroundNational guidelines for follow‐up care of childhood cancer survivors have been established. It has not been determined if pediatric oncology programs have successfully incorporated these standards for long term survivor care into clinical practice.MethodsTo describe survivor services available in a geographically and socio‐economically diverse region of the US we surveyed all 12 academic institutions with pediatric oncology programs in the New England (NE) region.ResultsParticipating sites diagnose a median of 34 (range 10–250) new pediatric cancers annually. The 12 institutions have 11 survivor clinics. Clinics are staffed by: pediatric oncologists (11/11); nurse practitioners (7/11); social workers/psychologists (9/11); RNs (5/11); primary care physicians (3/11); and sub‐specialists (3/11). Most clinics recommend annual follow‐up for all survivors (7/11); however, point of entry into survivor programs is variable. Treatment summaries and care plans are part of survivor care at each program. Almost all (10/11) refer to sub‐specialists to manage late effects. Only 4 programs identified a policy for transitioning survivors to adult care (2 to adult survivor programs, 2 to adult primary‐care) and 4 reported this as a problem. Two clinics had no designated funding for survivor services; 8/11 receive institutional support; 5/11 philanthropic. Five institutions conduct research in survivorship (1 government‐funded, 2 philanthropy‐funded, and 2 both).ConclusionsPediatric oncology services in the NE region are making progress toward meeting follow‐up care goals for childhood cancer survivors. Funding for resource intense programs, transitioning care to adult clinical services, volume of sub‐specialty referral, and participation in research are common challenges. Pediatr Blood Cancer 2011; 57: 1062–1066. © 2011 Wiley‐Liss, Inc.
Detection of MYCN DNA in the cerebrospinal fluid for diagnosing isolated central nervous system relapse in neuroblastoma
Authors: Kimoto Tomiko , Inoue Masami , Tokimasa Sadao , Yagyu Shigeki , Iehara Tomoko , Hosoi Hajime , Kawa Keisei 
Published: January 2011

AbstractWe present the case of a 1‐year‐old female with stage‐4 neuroblastoma with MYCN amplification; she was treated with five chemotherapy courses, resulting in normalization of elevated serum levels of tumor markers. Complete remission was achieved after allogeneic hematopoietic stem‐cell transplantation with reduced‐intensity conditioning. Nine months later, however, the tumor relapsed in the central nervous system (CNS). The serum and cerebrospinal fluid (CSF) levels of the tumor markers were normal, but the MYCN copy number was high only in the CSF DNA, suggesting an isolated CNS recurrence. The MYCN copy number in the CSF DNA was reflective of response to treatment. Pediatr Blood Cancer 2011;56:865–867. © 2011 Wiley‐Liss, Inc.
Oral low‐dose chemotherapy: Successful treatment of an alveolar rhabdomyosarcoma during pregnancy
Authors: Siepermann Meinolf , Koscielniak Ewa , Dantonello Tobias , Klee Dirk , Boos Joachim , Krefeld Barbara , Borkhardt Arndt , Hoehn Thomas , Asea Alexzander , Wessalowski Rüdiger 
Published: January 2011

AbstractWe report for the first time the impact of neoadjuvant oral low‐dose chemotherapy consisting of oral trofosfamide, idarubicin, and etoposide (O‐TIE) in the case of alveolar rhabdomyosarcoma (RMS) in the lower jaw of an 18‐year‐old woman at 27 weeks of gestation, without fetal complications and a highly efficient anti‐tumor response. Our study suggests the possible application of O‐TIE treatment in a neoadjuvant setting during pregnancy and recommends a schedule that can be considered for the treatment of patients with high‐risk sarcomas who cannot be treated with intensive chemotherapy for various reasons. Pediatr Blood Cancer 2012; 58: 104–106. © 2011 Wiley Periodicals, Inc.